Cato strategic partnership and appoints US CMO
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Neuren Initiates NNZ2566 Oral Formulation Development
- Neuren Completes Additional Phase I Study for TBI
- Neuren reduces outstanding convertible note principal
- Neuren Completes Phase II trial Cohort 1
- Neuren Rights Issue Offer Document (NZ residents)
Later from Neuren Pharmaceuticals
- Neuren awarded Rett Syndrome trial grant
- First subject commences Neurens Rett syndrome Phase 2 trial
- Results of Phase 2 trial in moderate to severe TBI
- Grant of new patent for Autism Spectrum Disorders
- Neuren presents at Rettsyndrome.org 2016 Research Symposium
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals